The Brand Name NEXVENIA Has Generic Salt :: DESVENLAFAXINE 

NEXVENIA  Is From Company ALKEM Priced :: Rs. 78

NEXVENIA have DESVENLAFAXINE is comes under Sub class Anti Depressants of  Main Class Nervous System

Main Medicine Class:: Nervous System  Sub Medicine Class :: Anti Depressants 

Indications for Drugs ::

Depression

Drug Dose ::

Oral Depression Adult: 50 mg once daily. Doses up to 400 mg once daily have been studied and shown to be effective, but no additional benefit was observed with doses >50 mg once daily. Renal impairment: CrCl (ml/min) 30-50 mL/min 50 mg once daily. <30 mL/min or ESRD 50 mg every other day. Additional doses should not be given after dialysis. Hepatic impairment: 50 mg once daily. Doses >100 mg/day are not advised.

Contraindication ::

Hypersensitivity to Desvenlafaxine, venlafaxine or any component of the formulation. Concomitant/recent (within preceeding 14 days) use of MAOI. Do not initiate MAOI at least 7 days after discontinuing Desvenlafaxine.

Drug Precautions ::

May be associated with increased risk of suicidal thinking and behaviour in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Monitor patients for clinical worsening of depression, emergence of suicidality, unusual changes in behaviour particularly during initiation of therapy and during dosage adjustments. Serotonin syndrome or neuroleptic malignant syndrome (NMS) have occurred with selective serotonin reuptake inhibitor (SSRI) or SNRI treatment alone; and particularly with concomitant use of MAOI, serotogenic agents (e.g. triptans), antipsychotics or dopamine antagonists. Gradually taper dose if discontinuing to reduce risk of withdrawal symptoms. May activate mania/hypomania, caution in patients with history or family history of mania or hypomania. Caution in patients with pre-existing glaucoma, hypertension, cardiovascular, cerebrovascular, or lipid metabolism and seizure disorders. Sustained elevations in blood pressure have been reported. May be associated with dose-related increase in serum total cholesterol, LDL, triglycerides. May increase risk of bleeding. May be associated with development of syndrome of inappropriate antidiuretic hormone (SIADH) and Hyponatraemia, elderly and patients who are taking diuretics or with volume depletion may be at greater risk. Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of desvenlafaxine) have been reported. Medications containing venlafaxine should not be used concomitantly. Renal and hepatic impairment. Safety and efficacy have not been established in paediatrics. Elderly. Pregnancy. Not recommended in lactation.

Drug Side Effects ::

Dizziness, nausea, vomiting, dry mouth, headache, tinnitus, insomnia, abnormal dreams, fatigue, constipation, diarrhoea, somnolence, decreased appetite, irritability, anxiety, tremor, paresthesia, male sexual function disorders (e.g. decreased libido, delayed ejaculation, erectile dysfunction), urinary hesitancy, hyperhidrosis, blurred vision, mydriasis, palpitations, hypertension, orthostatic hypotension, dyslipidemia, proteinuria, and abnormal liver function test. Potentially Fatal: Serotonin syndrome or neuroleptic malignant syndrome-like reactions.

Pregnancy category ::

3

Drug Mode of Action ::  

Desvenlafaxine, the major active metabolite of venlafaxine, is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). Clinical efficacy of desvenlafaxine is thought to be related with the drug’s potentiation of serotonergic and noradrenergic activity in the CNS. It does not have monoamine oxidase (MAO) inhibitory activity; and has not shown significant affinity for muscarinic cholinergic, H1-histaminergic, ?-adrenergic, dopaminergic, ?-aminobutyric acid (GABA), glutamate, and opiate receptors in vitro. At concentrations that inhibit serotonin and norephinephrine reuptake, inhibition of dopamine reuptake appears to be unlikely.

Drug Interactions ::

Desvenlafaxine may diminish the therapeutic effect of Iobenguane I-123. May enhance adverse effects of other CNS depressants. Sibutramine and MAOI may enhance the serotonergic effect of Desvenlafaxine; increase risk of development of serotonin syndrome. Concomitant use with alpha-/beta-agonists may enhance tachycardic and vasopressor effect. Desvenlafaxine may increase concentration of CYP2D6 substrates (e.g. desipramine); decrease exposure of CYP3A4 substrates (e.g. midazolam). CYP3A4 inhibitors (e.g. ketoconazole) may increase concentration of desvenlafaxine. May enhance the antiplatelet effect of nonselective NSAIDs, aspirin; and anticoagulant effect of warfarin. Potentially Fatal: Concurrent use with MAOIs may lead to fatal serotonin syndrome or NMS-like reactions. Do not use within at least 14 days of discontinuing MAOI treatment and start MAOI at least 7 days after stopping desvenlafaxine. Increased risk of serotonin syndrome with sibutramine.